Premium
Clinical safety of haloprogin, a new topical antimicrobial
Author(s) -
Hermann Harold W.
Publication year - 1973
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1973141100
Subject(s) - phototoxicity , medicine , dermatology , antimicrobial , sensitization , allergic contact dermatitis , penetration (warfare) , toxicity , pharmacology , allergy , immunology , chemistry , microbiology and biotechnology , biology , biochemistry , operations research , in vitro , engineering
Extensive clinical safety studies indicate that one per cent haloprogin cream is safe for repeated topical applications. Its potential for irritancy, allergic contact sensitization, phototoxicity, or allergic contact photosensitization was low. There was no evidence of systemic toxicity elicited by repeated massive dermal applications. In dermal penetration studies it was concluded that the penetration of haloprogin through the skin was of a low order of magnitude.